Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cerevel Therapeutics Hldg Inc (NQ: CERE ) 44.96 UNCHANGED Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cerevel Therapeutics Hldg Inc < Previous 1 2 3 4 5 6 Next > CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm June 18, 2024 From The Schall Law Firm Via Business Wire CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm June 11, 2024 From Kaskela Law LLC Via Business Wire Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses June 05, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 10 Health Care Stocks Whale Activity In Today's Session June 04, 2024 Via Benzinga Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses May 29, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? May 20, 2024 Revenue growth during what should be a disastrous patent cliff is encouraging. Via The Motley Fool Topics Intellectual Property Exposures Intellectual Property CERE Stock Earnings: Cerevel Therapeutics Hldg Misses EPS for Q2 2024 May 09, 2024 CERE stock results show that Cerevel Therapeutics Hldg missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study April 18, 2024 Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed. Via Benzinga Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug April 15, 2024 The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. Via Investor's Business Daily Tuesday Talk: Big-Tech Under Attack March 26, 2024 On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. Via Talk Markets Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? March 25, 2024 AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease. Via Benzinga 3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 March 09, 2024 Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. Via InvestorPlace Is AbbVie Stock a Buy Now? February 22, 2024 Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable. Via The Motley Fool This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space February 16, 2024 Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... Via Benzinga UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst February 06, 2024 UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. Via Benzinga AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall February 02, 2024 AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products. Via Benzinga AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures January 29, 2024 AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield. Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq – January 29, 2024 From Brodsky & Smith LLC Via GlobeNewswire ABBV: This Top Biotech Just Went On A Buying Spree January 25, 2024 AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). Via Talk Markets 7 Dividend Aristocrats That Will Pay You for Years to Come January 22, 2024 If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024. Via InvestorPlace CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders January 08, 2024 From Halper Sadeh LLC Via Business Wire 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday January 08, 2024 The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. Via Benzinga Is AbbVie Stock a Buy Now? January 07, 2024 The company is grappling with losing Humira's patent protection in 2023. Via The Motley Fool Topics Intellectual Property Exposures Intellectual Property BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. January 04, 2024 From Brodsky & Smith LLC Via GlobeNewswire Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Via Benzinga JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know December 28, 2023 Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. December 26, 2023 From Brodsky & Smith LLC Via GlobeNewswire Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday December 22, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. December 18, 2023 From Brodsky & Smith LLC Via GlobeNewswire The 7 Most Undervalued Growth Stocks to Buy in December December 13, 2023 Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback. Via InvestorPlace < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
